Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Rutgers Cancer Institute of NJ

Rutgers Cancer Institute of New Jersey Names Dr. Janet Gordils-Perez Chief Nursing Officer

Dr. Janet Gordils-Perez

New Brunswick, NJ, August 3, 2017 — Janet Gordils-Perez, DNP, RN, ANP-BC, AOCNP, from Plainsboro Township, has been promoted to Chief Nursing Officer at Rutgers Cancer Institute of New Jersey.  She had served as Director of Oncology Nursing.

Dr. Gordils-Perez came to Rutgers Cancer Institute in 2004 from Memorial Sloan-Kettering Cancer Center, where she was an adult nurse practitioner and a clinical research nurse. Continue reading

Rutgers Cancer Institute of New Jersey Investigators Receive $450K in Fellowship Grants

New Brunswick, NJ, July 27, 2017 — Rutgers Cancer Institute of New Jersey investigators have received $450,000 in funding to support research projects in immunotherapy and basic science research that could impact pancreatic, breast and other cancers.

The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).

Eileen White, Ph.D., Rutgers Cancer Institute Deputy Director, Chief Scientific Officer and Associate Director for Basic Science, said, “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is dedicated to treatment, prevention, education and research.” Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, July 18, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

Rutgers Q&A: Dr. Perry Halkitis, Openly Gay Dean of Rutgers School of Public Health, Seeks to Shatter Perceptions, Improve LGBTQ Health

Dr. Perry Halkitis

New Brunswick, NJ, June 20, 2017 — When Perry N. Halkitis, Ph.D., the incoming dean at Rutgers School of Public Health, is asked to discuss the accomplishments that make him most proud, his research in HIV/AIDS, his mentorship of young scholars and practitioners, and his roles as senior associate dean of New York University’s College of Global Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies come to the fore.

But equal to those achievements is Dr. Halkitis’ identity as an openly gay man in academia and a first-generation college student.

Halkitis, who will join Rutgers in August, is enthusiastic about furthering the research he pursued at NYU. Continue reading

Sen. Menendez Visits Rutgers Cancer Institute to Illustrate Impact of Trump Proposed Budget Cuts on Lifesaving Biomedical Research that Leads to New Cures, Treatments

Sen. Bob Menendez and (l.) Dr. Steven Libutti

New Brunswick, NJ, April 13, 2017 — During a visit yesterday to the Rutgers Cancer Institute of New Jersey, U.S. Senator Bob Menendez and several of the state’s top biomedical researchers and experts, outlined the devastating impact the Trump Administration’s proposed budget cuts to the National Institutes of Health (NIH) would have on lifesaving biomedical research, and treatments of diseases and neurological disorders.

New Jersey is the nation’s second largest recipient of NIH funding in the nation.

“A budget is a reflection of priorities,” said Sen. Menendez.  “The cuts proposed by the Trump Administration send a message that the research being done right here by some of nation’s most brilliant minds is not a priority.”

“It says the breakthrough discoveries that could potentially help someone like my mother in her fight against Alzheimer’s or give a terminally-ill child a shot at a healthy, happy life – is not worthy of federal investment,” Menendez added.  “That’s not a message I want to send.” Continue reading

Rutgers Cancer Institute of NJ Resident Receives $1.8M Grant to Explore Chronic Stress Role in Cancer Development

Wenwei Hu, Ph.D.

Wenwei Hu, Ph.D.

New Brunswick, NJ, January 28, 2017 — A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, Ph.D., will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors – p53.

The aim is to explore how chronic stress impacts cancer development, especially when cancers containing a mutation in p53, and identify molecular targets that would disrupt the effect of chronic stress on cancer development.

The p53 protein plays a central role in preventing cancer development, as loss of its tumor suppressor function has been shown to contribute greatly to cancer development. Continue reading

New Director of Rutgers Cancer Institute of NJ Outlines 2017 Goals

Dr. Steven K. Libutti

Dr. Steven K. Libutti

New Brunswick, NJ, January 27, 2017 — Minna Kim reports that the Rutgers Cancer Institute of New Jersey (RCINJ) began the new year under the leadership of new Director Steven Libutti, who assumed the position on January 10.

One immediate responsibility that the new director will hold is ensuring that RCINJ is renewed as one of the 47 designated Comprehensive Care Centers of the National Cancer Institute (NCI).  This will be determined one year from now, Libutti said.

“Competitive grants are awarded to cancer centers that exceed certain criteria, that and expectations that the National Cancer Institute sets,” he said.  “Every five to seven years, we have to re-compete for the designation and grant.” Continue reading

Event: HINJ to Co-Sponsor Rutgers-Industry Cancer Research Symposium on January 24

Rutgers CINJ LogoNew Brunswick, NJ, January 18, 2017 — The HealthCare Institute of New Jersey (HINJ) is pleased to co-sponsor a Rutgers-Industry Cancer Symposium that will be presented on Tuesday, January 24 from 4:00 to 6:00 p.m. in Auditorium A and B at the Rutgers Cancer Institute of New Jersey at 195 Little Albany Street, New Brunswick.

This series is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners.

At the January 24 symposium, Rutgers researchers will present an update on clinical investigations.

In addition, Incyte Corporation will present an update on drugs in its pipeline.

Registration is not required.  For the event flyer, click here.

Rutgers Cancer Institute of NJ Awarded $50,000 to Support Childhood Cancer Research

Rutgers CINJ LogoNew Brunswick, NJ, December 13, 2016 — Childhood cancer patients depend on clinical trials to find better, safer cures that can prevent lifelong damage as a result of radiation and chemotherapy.  Rutgers Cancer Institute of New Jersey will receive an infrastructure grant from the St. Baldrick’s Foundation to expand access to their clinical trials.

Despite the increase of childhood cancer survival rates in the last two decades, adolescent and young adult (AYA) patients have had minimal improvement in cure rates. Contributing to this statistic is the AYA population’s low numbers of participation in clinical trials. Continue reading

Dr. Steven Libutti to Serve Dual Rutgers Roles: Cancer Institute Director and Rutgers Biomedical and Health Sciences Vice Chancellor

Dr. Steven K. Libutti

Dr. Steven K. Libutti

New Brunswick, NJ, November 18, 2016 — Aiming to further propel scientific discovery as well as augment and expand comprehensive cancer services for patients through collaborative efforts with Rutgers and RWJBarnabas Health, Steven K. Libutti, M.D., FACS, has been named to serve in the dual positions of Director of Rutgers Cancer Institute of New Jersey and of Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences.

When he takes on his new roles in early 2017, Dr. Libutti will be the third permanent director in the 25-year history of Rutgers Cancer Institute of New Jersey and will take over for Bruce G. Haffty, MD, who has been serving as interim director and will continue his role as Chair of Radiation Oncology.

Dr. Libutti also will have an appointment as a Professor of Surgery at Rutgers Robert Wood Johnson Medical School. Continue reading